Skip to main content
Premium Trial:

Request an Annual Quote

Shivom, Lifebit Partner on DNA Analysis Platform for Clinical Trials

NEW YORK (GenomeWeb) — Shivom said today that it has partnered with Lifebit to offer an artificial intelligence-powered platform for identifying the right patients for enrollment in clinical trials.

Shivom was founded in 2017 by Munich-based Omix Ventures to develop a decentralized genomic data ecosystem based on blockchain, a technology for securely tracking and recording online transactions in a way that cannot be manipulated by any one entity. London-based Lifebit, also launched in 2017, recently introduced a cloud-based genomic analysis platform called Deploit.

Under the terms of the deal, the companies will combine their respective technologies to offer a DNA data platform that Shivom said will allow users to perform immediate genome-wide association study analyses, and access proprietary software and AI-powered tools for data analysis.

Additional terms were not disclosed.

"Through this partnership with Lifebit, we are providing enterprise users with the tools they need to find the right patients for their clinical trials more easily and more accurately than is possible through other solutions," Shivom Cofounder and CSO Axel Schumacher said in a statement. "Not only that, it brings AI into GWAS analysis in a way that hasn't been seen before."

The deal marks the latest alliance forged by Shivom, which has partnerships with nonprofit eMQT to sequence the genomes of 1,000 sickle-cell disease patients in sub-Saharan Africa; SingularityNet on genomic and medical analytics; and Genetic Technologies to build a genomic data platform for diagnostic development.

Schumacher recently said that Omix is also establishing a non-profit arm of the company called the Shivom Foundation.

The Scan

Call for a Different Tack

Experts weigh the value of recent experiments testing genetically modified pig kidneys using brain-dead individuals, according to Nature News.

Wastewater Warning

The New York Times reports that wastewater surveillance in some parts of the US point to a possible surge.

Can't Get in the Program

Due to the Northern Ireland protocol dispute, the European Union is preventing UK researchers from joining the Horizon Europe research program, the Times of London reports.

Science Paper on Spatial-Controlled Genome Editing

In Science this week: approach to enable a CRISPR-Cas13a-based system to be used as a cancer therapy.